Publications

Comparative Risk of Incident and Recurrent Acute Anterior Uveitis across Different Biological Agents in Patients with Ankylosing Spondylitis

DOI 10.1093/rheumatology/keae003 Epub ahead of print

Kwon OC,

Lee HS,

Yang J,

Park MC

Kwon, et al. found that adalimumab exposure significantly reduced risk of incident and recurrent acute anterior uveitis (AAU) versus etanercept exposure and bDMARD non-exposure. Furthermore, exposure to etanercept significantly increased risk of incident and recurrent AAU versus bDMARD non-exposure.

Keywords:

• Golilumab,
• Ixekizumab,
• Real-World,
• Safety,
• TNF

Efficacy of Pharmacological Interventions: A Systematic Review Informing the 2023 EULAR Recommendations for the Management of Fatigue in People with Inflammatory Rheumatic and Musculoskeletal Diseases

RMD Open 2023;9(4):e003349 doi 10.1136/rmdopen-2023-003349

Farisogullari B,

Santos EJF,

Dures E,

Geenen R,

Machado PM

Adalimumab demonstrated superiority over placebo in reducing fatigue in RA at 12 and 52 weeks. Other interventions, which included golimumab, baricitinib, sarilumab, tocilizumab, and tofacitinib, also proved effective in reducing fatigue in patients with RA. Secukinumab also reduced fatigue by Week 52 in patients with SpA.

Keywords:

• Baricitinib,
• Efficacy,
• Fatigue,
• Golilumab,
• Safety,
• Secukinumab

Efecto de golimumab intravenoso en la fatiga y la relación con la respuesta clínica en adultos con espondilitis anquilosante activa en el estudio de fase 3 estudio de fase 3 GO-ALIVE

Rheumatol Ther. 2023;10(4):983–999 doi 10.1007/s40744-023-00556-y

Deodhar A,

Shiff NJ,

Gong C,

Chan EK,

Hsia EC,

Lo KH,

Akawung A,

Kim L,

Xu S,

Reveille JD

Administration of IV-golimumab 2 mg/kg improves fatigue symptoms in axial spondylitis in a 52 Week study. At Week 16 of treatment, improvements in ASAS, ASDAS, BASDAI and SF-36 scores were observed at week 16 of treatment.

Keywords:

• TNF,
• Golilumab,
• Phase 3,
• Efficacy,
• Fatigue

Eficacia y Seguridad de Golimumab en Pacientes con Espondiloartritis Axial no Radiográfica: Un estudio de Retirada y Retratamiento (GO-BACK)

Rheumatology (Oxford) 2023;62(11):3601–3609 doi: 10.1093/rheumatology/kead112

Weinstein CLJ,

Sliwinska-Stanczyk P,

Hála T,

Stanislav M,

Tzontcheva A,

Yao R,

Berd Y,

Curtis SP,

Phillip G

This study highlighted that continued treatment with Golimumab (GLM) QMT or GLM Q2MT was superior to placebo. The GO-BACK study was designed to evaluate the efficacy and safety of golimumab treatment withdrawal in adults with nr-axSpA who demonstrate inactive disease during a 10-month open label GLM run-in.

Keywords:

• TNF,
• Golilumab,
• Efficacy,
• Safety,
• Dosing

Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis – A nationwide cohort study from the DANBIO and DERMBIO registries

Semin Arthritis Rheum. 2022 doi: 10.1016/j.semarthrit.2022.151979

Egeberg A,

Rosenø NAL,

Aagaard D,

Lørup EH,

Nielsen M,

Nymand L,

Kristensen L,

Thyssen J,

Thomsen S,

Cordtz R,

Loft N,

Skov L,

Bryld L,

Rasmussen M,

Højgaard P,

Kristensen S,

Dreyer L

The authors reviewed drug survival of therapies across common inflammatory skin and joint conditions from national registries.  The findings highlighted that despite the overlapping pathogenesis of these conditions there was little similarity in drug survival. This reinforces the need for an individualised treatment approach consistent with the underlying disease, patient profile and treatment history.

Keywords:

• Real-World,
• Efficacy

Metanálisis en Red de Tofacitinib versus Tratamientos Biológicos en Pacientes con Artritis Reumatoide Moderada a Grave

J Clin Pharm Ther. 2019 Jun;44(3):384-396.

Camean‐Castillo M,

Gimeno‐Ballester V,

Rios‐Sanchez E,

Fenix‐Caballero S,

Vázquez‐Real M,

Alegre‐del Rey E

This study suggests that many bDMARDs and tsDMARDs can be considered equivalent therapeutic alternatives in bDMARD-naïve RA patients, with inadequate response to csDMARDs.In the absence of randomised controlled trials comparing drugs, indirect comparisons and network meta-analysis may provide information to help select an optimal treatment alternative. In this network meta-analysis, 27 randomized controlled trials were analysed to assess the possibility that some drugs on the market may be consi...

Keywords:

• JAK,
• Tildrakizumab,
• Efficacy,
• Safety,
• Meta analysis

Biológicos o Tofacitinib para personas con Artritis Reumatoide naïve a metotrexate: Una revisión Sistemática y Metaanálisis en red

Cochrane Database Syst Rev. 2017 May 8;5:CD012657. doi: 10.1002/14651858.CD012657

Singh JA,

Hossain A,

Tanjong Ghogomu E,

Mudano AS,

Tanjong Ghogomu E,

Suarez-Almazor ME,

Buchbinder R,

Maxwell LJ,

Tugwell P,

Wells GA

This Cochrane systemic review and network meta-analysis looked at the benefits and harms of biologics or tofacitinib in patients with RA not previously treated with MTX.Using data from 19 RCTs including 6,485 participants, the review found that biologics (abatacept, adalimumab, etanercept, golimumab, infliximab, rituximab) in combination with MTX improved signs and symptoms of RA (ACR50) and increased the chances of remission (DAS <1.6 or DAS28 <2.6). There was also some evidence of an improveme...

Keywords:

• JAK,
• Tofacitinib,
• Meta analysis,
• Review

Tofacitinib Versus Biologic Treatments in Patients with Active Rheumatoid Arthritis who have had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results from a Network Meta-Analysis

Clin Ther 2016;38:2628–40.

Vieira M-C,

Zwillich SH,

Jansen JP,

Smiechowski B,

Spurden D and Wallenstein GV

This network meta-analysis, performed within a Bayesian framework, concluded that tofacitinib 5 mg BID has efficacy and AE rates comparable with currently available bDMARDs over a 24-week period in patients experiencing an inadequate response to TNF therapy. A systematic literature search identified five, Phase 2 or beyond, randomised controlled trials for inclusion in the analysis. Each trial had an adult population with moderate to severe RA, with inadequate response (IR) or failed treatment w...

Keywords:

• JAK,
• Tofacitinib,
• Meta analysis

Biologic or Tofacitinib Monotherapy for Rheumatoid Arthritis in People with Traditional Disease-modifying Anti-rheumatic Drug (DMARD) Failure: a Cochrane Systematic Review and Network meta-analysis (NMA)

Cochrane Database Syst Rev 2016;11:CD012437.

Singh JA,

Hossain A,

Tanjong Ghogomu E,

Mudano AS,

Tugwell P,

Wells GA

Treatment options for RA patients who are MTX/DMARD incomplete responders (IR) include other DMARDs, biologics or tofacitinib (TOF). However, there is a lack of direct head-to-head comparator trials of biologics in people with RA. This review provides an update of the 2009 Cochrane overview, ‘Biologics for rheumatoid arthritis’,1 and provides comparisons and estimates for biologic or TOF monotherapy in MTX/DMARD-IR people with RA.The benefits and harms of biologic monotherapy (TNFis: adalimumab,...

Keywords:

• JAK,
• Tofacitinib,
• Meta analysis

Biologics or Tofacitinib for Rheumatoid Arthritis in Incomplete Responders to Methotrexate or Other Traditional Disease-Modifying Anti-Rheumatic Drugs: A Systematic Review and Network Meta-Analysis

Cochrane Database of Systematic Reviews 2016 Issue 5. Art. No.: CD012183 [DOI: 10.1002/14651858.CD012183].

Singh et al

Treatment options for RA patients who are MTX/DMARD incomplete responders (IR) include other DMARDs, biologics or tofacitinib (TOF). However, there is a lack of head-to-head studies to show any important differences between these options in terms of benefits and harms. This review provides an update of the 2009 Cochrane overview and network meta-analysis (NMA) of biologics for RA.1Nine biologics (abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, a...

Keywords:

• JAK,
• Tofacitinib,
• Meta analysis